| |
| |
Jonathan L. Halperin, MD
|
|
Mount Sinai School of Medicine
Director, Clinical Cardiology Services
The Zena and Michael A. Wiener Cardiovascular Institute
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
Mount Sinai Medical Center
Fifth Avenue at 100th Street
New York, New York
USA Jonathan L. Halperin, MD, is the Robert and Harriet Heilbrunn Professor of Medicine at Mount Sinai School of Medicine, Director of Clinical Cardiology Services in the Zena and Michael A. Wiener Cardiovascular Institute at The Mount Sinai Medical Center. Educated at Columbia University and Boston University School of Medicine, Dr Halperin played a key role in the formation of the Cardiovascular Institute, one of the nation's leading centers for integrated cardiovascular research, education and patient care, and is Past-President of the New York City Affiliate of the American Heart Association, the Society for Vascular Medicine and Biology.
Dr Halperin was the principal cardiologist responsible for the design and execution of the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, sponsored by the National Institutes of Health. These multicenter studies, which involved 3,600 patients and over 100 investigators, helped develop antithrombotic strategies to prevent stroke among the more than two million North Americans with atrial fibrillation. Most recently, he served as Co-Chairman of the Executive Steering Committee of the SPORTIF clinical trials, which evaluated an oral thrombin inhibitor for prevention of stroke in patients with atrial fibrillation. These international trials, involving over 7,000 patients randomized at over 700 clinical centers in 25 nations, represent the most aggressive effort ever mounted against embolic stroke and introduce an innovative antithrombotic strategy with potential applications in a wide array of cardiovascular disorders. |